6 completed. 6 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 6 |
| Phase 1 | 4 | Completed 4 |
| Phase 3 | 1 | Completed 1 |
Follow Sensorineural Hearing Loss: new trials by email Literature Review of Sensorineural Hearing Loss trials Research Report on Sensorineural Hearing Loss
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I/IIa Study Evaluating Safety and Efficacy of an Intratympanic Dose of PIPE-505 in Subjects With Hearing Loss PIPE-505, Placebo - Sensorineural Hearing Loss | Phase 1 / Phase 2 | Completed | Contineum Therapeutics | 28 | 2020-10-15 | 2025-04-01 |
| FX-322 in Adults With Stable Sensorineural Hearing Loss FX-322 (One Dose), FX-322 (Two Doses), FX-322 (Four Doses) - Sensorineural Hearing Loss, Noise Induced Hearing Loss | Phase 2 | Completed | Frequency Therapeutics | 95 | 2019-10-04 | 2023-04-27 |
| OTO-413 in Subjects With Speech-in-Noise Hearing Impairment OTO-413, Placebo - Sensorineural Hearing Loss | Phase 1 / Phase 2 | Completed | Otonomy, Inc. | 110 | 2019-10-01 | 2022-10-27 |
| FX-322 in Sensorineural Hearing Loss FX-322, Placebo - Sensorineural Hearing Loss | Phase 1 / Phase 2 | Completed | Frequency Therapeutics | 23 | 2018-07-03 | 2022-11-14 |
| Evaluation of a Binaural Spatialization Method for Hearing Aids Hearing Aids - Sensorineural Hearing Loss | Phase 2 / Phase 3 | Completed | Sonova AG | 40 | 2016-02-01 | 2016-10-04 |
| A Clinical Trial of Anakinra for Steroid-Resistant Autoimmune Inner Ear Disease Anakinra - Sensorineural Hearing Loss, Autoimmune Inner Ear Disease | Phase 1 / Phase 2 | Completed | Andrea Vambutas | 13 | 2011-06-01 | 2018-01-10 |
Hearing Loss, Sensorineural (6) · Hearing Loss (2) · Hearing Loss, Hidden (2) · Hearing Loss, Sudden (2) · Deafness (1) · Hearing Loss, Noise-Induced (1) · Meniere Disease (1)
Ear Diseases (6) · Hearing Disorders (6) · Nervous System Diseases (6) · Neurologic Manifestations (6) · Otorhinolaryngologic Diseases (6) · Pathological Conditions, Signs and Symptoms (6) · Sensation Disorders (6) · Signs and Symptoms (6) · Hearing Loss (4) · Endolymphatic Hydrops (1) · Labyrinth Diseases (1)
Hearing Aids (1) · Interleukin 1 Receptor Antagonist Protein (1)
Frequency Therapeutics (2) · Andrea Vambutas (1) · Contineum Therapeutics (1) · Otonomy, Inc. (1) · Sonova AG (1)
United States (5) · Switzerland (1)
Andrea Vambutas, MD (1) · Carl LeBel, PhD (1) · George Atiee, MD (1) · Gilles Courtois, Enginner (1) · Stephen Huhn, MD (1)
PMID 25133431, PMID 29457537, PMID 42479273
R33DC011827 (1)